LIPOHYPERTROPHY IN CSII* PATIENTS AND ITS RELATIONSHIP TO KEY CLINICAL PARAMETERS

Smith M, Baggott A, Green E, Strauss K, Kelly P. Plymouth Diabetes Centre, Derriford Rd, Crownhill, Plymouth PL6 8DH, UK


INTRODUCTION:

Lipohypertrophy (LH) is found in up to half of insulin injecting patients and is associated with higher HbA1c, higher total daily doses (TDD) and more frequent hypoglycaemia and glycaemic variability. However little is known about the prevalence of LH in CSII patients or its clinical significance.

METHODS:

We assessed for LH in 70 CSII patients and analysed its impact on key clinical parameters.

RESULTS:



DISCUSSION:

LH is present in nearly 3 out of 5 CSII patients and palpation picks up more LH than visualization alone. In our CSII patients LH is not related to HbA1c, TDD, hypoglyaemia, glycaemic variability or DKA, suggesting that the mechanism and clinical implications in CSII patients may differ from those in insulin injectors.